OncoLens

OncoLens has enabled hundreds of breast cancer programs deliver, timely precision cancer care. Whether it is related to finding patients at the right time for germline testing, precision medicine, clinical trials or for quality programs like NAPBC, we are happy to share best practices and lessons learnt. Come talk to us next week!

On July 28, 2023, the Commission on Cancer National Cancer Data Base (NCDB) RCRS introduced updates to three Quality Measures.

Leveraging advancements in Artificial Intelligence (AI) can significantly simplify the process to stay on top of these measures.

Read more about which quality measures have changed and how OncoLens can help: https://www.oncolens.com/blog/strategies-for-enhancing-hospital-programs-accreditation-quality-metric-tracking/

“Partnering with new sites to build up access in areas with underserved and hard-to-reach patient populations can be largely advantageous for hitting diversity enrollment goals.”

This June 28, 2023 article by the American Association for Cancer Research (AACR) outlines pertinent operational strategies to address Diversity and Inclusion in clinical trials including:

1) Use available data and tools to identify opportunities to enroll and retain diverse patients
2) Expand established partnerships and establish new ones
3) Engage early with sites to align expectations and identify facilitators and challenges to meeting them.

Read the full report here:

https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-23-1391/727437/Driving-Diversity-and-Inclusion-in-Cancer-Drug?searchresult=1